Perspectives and limitations in the treatment of vagus-induced atrial fibrillation. Insights from cellular pharmacology;Effektivität und proarrhythmie bei der pharmakologischen behandlung des vagal induzierten vorhofflimmerns. Erkenntnisse aus der zellulären pharmakodynamik

Medizinische Klinik

Volumn 99, Issue 7, 2004, Pages 341-346

  Brandts, Bodo ^a   Van Bracht, Marc ^b   Dirkmann, Daniel ^b   Borchard, Rolf ^b   Wickenbrock, Ingo ^b   Prull, Magnus Wilhelm ^b   Meine, Mathias ^b   Trappe, Hans Joachim ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b NONE

Author keywords

Antiarrhythmic drug; Atrial fibrillation; Atrial myocyte; IK(ACh); Nervus vagus

Indexed keywords

ACETYLCHOLINE; CHROMANOL 293B; DOFETILIDE; IBUTILIDE; SOTALOL; TERIKALANT;

ANIMAL CELL; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; HEART ATRIUM FIBRILLATION; IC 50; INHIBITION KINETICS; MUSCLE CELL; NONHUMAN; POTASSIUM CURRENT; RAT; REVIEW; VAGUS INDUCED HEART ATRIUM FIBRILLATION; VAGUS NERVE; VOLTAGE CLAMP;

ANIMALIA;

EID: 3242675209     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-004-1051-4     Document Type: Review

References (29)

1. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995;155:469-78.
2. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med 1987;317:669-74.
3. Haïssaguerre M, Jäis P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.
4. Jaïs P, Haïsaguerre M, Shah DC, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997;95:572-6.
5. Hwang C, Karagueuzian HS, Chen PS. Idiopathic paroxysmal atrial fibrillation induced by a focal discharge mechanism in the left superior pulmonary vein: possible roles of the ligament of Marshall. J Cardiovasc Electrophysiol 1999;10:636-48.
6. Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999;100:1879-86.
7. Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. Am Heart J 1964;67:200-20.
8. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation 2002;105:2753-9.
9. Tsikouris JP, Cox CD. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm. Pharmacotherapy 2001;21:1514-29.
10. Kowey PR, Marinchak RA, Rials SJ, et al. Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs. Am J Cardiol 1997;80:16G-23G.
11. Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 1999;84:20R-8R.
12. Doggrell SA. Amiodarone - waxed and waned and waxed again. Expert Opin Pharmacother 2001;2:1877-90.
13. Auer J, Berent R, Eber B, Amiodarone in the prevention and treatment of arrhythmia. Curr Opin Investig Drugs 2002;3:1037-44.
14. Singh BN. Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol 1997;20:608-18.
15. Vrobel TR, Miller PE, Mostow ND, et al. A general overview of amiodarone toxicity: its prevention, detection, and management. Prog Cardiovasc Dis 1989;31:393-426.
16. Spaniol M, Bracher R, Ha HR, et al. Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J Hepatol 2001;35:628-36.
17. Reasor MJ, Kacew S. An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity. Proc Soc Exp Biol Med 1996;212:297-304.
18. Fernando Roth R, Itabashi H, Louie J, et al. Amiodarone toxicity: myopathy and neuropathy. Am Heart J 1990;119:1223-5.
19. Beddows SA, Page SR, Taylor AH, et al. Cytotoxic effects of amiodarone and desethylamiodarone on human thyrocytes. Biochem Pharmacol 1989;38:4397-403.
20. Weiss M. The anomalous pharmacokinetics of amiodarone explained by nonexponential tissue trapping. J Pharmacokinet Biopharm 1999;27:383-96.
21. Vadiei K, O'Rangers EA, Klamerus KJ, et al. Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function. J Clin Pharmacol 1996;36:720-7.
22. Pollak PT, Bouillon T, Shafer SL. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther 2000;67:642-52.
23. Najjar TA. Disposition of amiodarone in rats after single and multiple intraperitoneal doses. Eur J Drug Metab Pharmacokinet 2001;26:65-9.
24. Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 1999;84:20R-8R.
25. Bechem M, Pott L, Rennebaum H. Atrial muscle cells from hearts of adult guinea-pigs in culture: a new preparation for cardiac cellular electrophysiology. Eur J Cell Biol 1983;31:366-9.
26. Hamill OP, Marty A, Neher E, et al. Improved patch clamp techniques for high resolution current recording from cells and cell-free membrane patches. Pflügers Arch 1981;391:85-100.
27. Schauerte P, Scherlag BJ, Pitha J, et al. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation 2000;102:2774-80.
28. Dukes ID, Cleemann L, Morad M. Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. J Pharmacol Exp Ther 1990;254:560-9.
29. Castle NA. Selective inhibition of potassium currents in rat ventricle by clofilium and its tertiary homolog. J Pharmacol Exp Ther 1991;257:342-50.